A Phase 1 Open-Label Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-Talampanel Following Oral Administration to Healthy Male.
Phase of Trial: Phase I
Latest Information Update: 28 Oct 2015
At a glance
- Drugs Talampanel (Primary)
- Indications Amyotrophic lateral sclerosis; Dyskinesias; Epilepsy
- Focus Pharmacokinetics
- Sponsors Teva Pharmaceutical Industries
- 17 Sep 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 17 Sep 2009 Planned end date changed from 1 Jun 2009 to 1 Sep 2009 as reported by ClinicalTrials.gov.
- 28 Aug 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.